APC: Checking in on the post-Chevron fallout

FDA doubles down: Tirzepatide is off shortage

...but that doesn't mean the issue is completely settled. read more →
A couple of state updates

Good news from Alabama, but a problem in Massachusetts read more →
Defending GLP-1 compounding

The latest letters APC's been sending to oppose efforts to restrict compounding read more →
Thumbs-up for FDA crackdown

APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →
A PANS/PANDAS explainer

For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →
What, a year?

In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →
“Simply not a rational approach to regulating an industry”

This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →
Get a cease and desist letter from Verrica?

APC has heard reports from several pharmacies that have received them — here's what to know. read more →

November 8, 2024

Checking in on the post-Chevron fallout

What’s happened in the world of federal regulation since the Supreme Court overturned the decades-old Chevron doctrine in its Loper Bright decision? FDA Law Blog takes a look in “As Jurisprudence Under Loper Bright Develops, Early Scorecard is Mixed.”